• DOI:10.1517/14656566.4.6.999
Corpus ID: 16104816

Is natalizumab a breakthrough in the treatment of multiple sclerosis?

@article{Doggrell2003IsNA,
  title={Is natalizumab a breakthrough in the treatment of multiple sclerosis?},
  author={S. Doggrell},
  journal={Expert Opinion on Pharmacotherapy},
  year={2003},
  volume={4},
  pages={1001 - 999}
}

S. Doggrell

Published 2003

Medicine

Expert Opinion on Pharmacotherapy

In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated… CONTINUE READING

View on Taylor & Francis

direct-ms.org

Save to Library

Create Alert

Cite

Launch Research Feed